

Artemisinin and Derivatives Cancer Studies by Year

Cancer Types

▪ Breast	▪ Melanoma
▪ Cervical	▪ Multiple Myeloma
▪ CNS	▪ Oral
▪ Colorectal	▪ Ovarian
▪ Head & Neck	▪ Pancreatic
▪ Leukemia/Lymphoma	▪ Pituitary
▪ Liver	▪ Prostate
▪ Lung	▪ Sarcomas

2012

- (1) Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. *J Biomed Biotechnol.* 2012;2012:247597.
- (2) Eichhorn T *et al.* Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. *Mol Biosyst.* 2012 Apr;8(4):1311-8.
- (3) Gao J *et al.* Effect of dihydroartemisinin on the expression of BCR/ABL fusion gene in leukemia K562 cells. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* 2012 Feb;29(1):19-22
- (4) Jiang Z *et al.* Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. *Anticancer Drugs.* 2012 Mar 14
- (5) Ju HK *et al.* Standardized flavonoid-rich fraction of *Artemisia princeps* Pampanini cv. Sajabal induces apoptosis via mitochondrial pathway in human cervical cancer HeLa cells. *J Ethnopharmacol.* 2012 Mar 18
- (6) Lu JJ *et al.* Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. *Mol Cell Biochem.* 2012 Jan;360(1-2):329-37.
- (7) Mao ZG *et al.* Artesunate inhibits cell proliferation and decreases growth hormone synthesis and secretion in GH3 cells. *Mol Biol Rep.* 2012 May;39(5):6227-34
- (8) Tin AS *et al.* Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. *Anticancer Drugs.* 2012 Apr;23(4):370-9
- (9) Xiao F *et al.* Amplification activation loop between caspase-8 and -9 dominates artemisinin-induced apoptosis of ASTC-a-1 cells. *Apoptosis.* 2012 Mar 21

- (10) Wu B *et al.* Dihydroartemisinin inhibits the growth and metastasis of epithelial ovarian cancer. *Oncol Rep.* 2012 Jan;27(1):101-8.
- (11) Ye VM, Bhatia SK. Metabolic engineering for the production of clinically important molecules: Omega-3 fatty acids, artemisinin, and taxol. *Biotechnol J.* 2012 Jan;7(1):20-33
- (12) Zhang CZ *et al.* Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. *Biochem Pharmacol.* 2012 May 1;83(9):1278-89.
- (13) Zhou C *et al.* Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. *J Cell Physiol.* 2012 Feb 29.

2011 (29)

- (14) Alcântara DD *et al.* In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). *J Appl Toxicol.* 2011 Sep 23.
- (15) Aung W *et al.* Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. *Anticancer Res.* 2011 May;31(5):1549-58.
- (16) Bachmeier B *et al.* Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. *PLoS One.* 2011;6(5):e20550
- (17) Berdelle N *et al.* Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. *Mol Cancer Ther.* 2011 Dec;10(12):2224-33
- (18) Cabello CM *et al.* The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. *Invest New Drugs.* 2011 May 6
- (19) Chaijaroenkul W *et al.* Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. *Asian Pac J Cancer Prev.* 2011;12(1):55-9.
- (20) D'Alessandro S *et al.* Hypoxia modulates the effect of dihydroartemisinin on endothelial cells. *Biochem Pharmacol.* 2011 Sep 1;82(5):476-84.
- (21) Efferth T *et al.* Cytotoxic activity of secondary metabolites derived from *Artemisia annua* L. towards cancer cells in comparison to its designated active constituent artemisinin. *Phytomedicine.* 2011 Aug 15;18(11):959-69.
- (22) Fafowora MV *et al.* Effect of oral coadministration of artesunate with ferrous sulfate on rat liver mitochondrial membrane permeability transition. *Drug Chem Toxicol.* 2011 Jul;34(3):318-23.

- (23) Farsam V *et al.* Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. *Int Immunopharmacol.* 2011 Nov;11(11):1802-8
- (24) Gao N *et al.* Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. *Apoptosis.* 2011 Feb 19.
- (25) He R *et al.* An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. *PLoS One.* 2011;6(8):e24334.
- (26) Ji Y *et al.* Anti-tumor effects of dihydroartemisinin on human osteosarcoma. *Mol Cell Biochem.* 2011 Jan 14.
- (27) Kumar N *et al.* Medicinal chemistry perspectives of trioxanes and tetraoxanes. *Curr Med Chem.* 2011;18(25):3889-928.
- (28) Liu JJ *et al.* A new artemisinin derivative SM1044 induces apoptosis of Kasumi-1 cells and its mechanism. *Zhongguo Shi Yan Xue Ye Xue Za Zhi.* 2011 Jun;19(3):607-11
- (29) Ma H *et al.* The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. *Molecules.* 2011 Dec 19;16(12):10556-69.
- (30) Ricci J *et al.* Discovery of artemisinin-glycolipid hybrids as anti-oral cancer agents. *Chem Pharm Bull (Tokyo).* 2011;59(12):1471-5.
- (31) Schnepf N *et al.* Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. *Antiviral Res.* 2011 Feb;89(2):186-8.
- (32) Kumar N *et al.* Medicinal chemistry perspectives of trioxanes and tetraoxanes. *Curr Med Chem.* 2011;18(25):3889-928.
- (33) Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. *Cell Immunol.* 2011;271(1):67-72.
- (34) Singh NP *et al.* Cytotoxicity of ethanolic extracts of *Artemisia annua* to Molt-4 human leukemia cells. *Planta Med.* 2011 Nov;77(16):1788-93.
- (35) Singh NP *et al.* Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. *Anticancer Res.* 2011 Dec;31(12):4111-4.
- (36) Tan W *et al.* Anti-cancer natural products isolated from chinese medicinal herbs. *Chin Med.* 2011 Jul 22;6(1):27
- (37) Thanaketaipaisarn O *et al.* Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF- κ B and PI3K/Akt signaling pathways. *Int J Oncol.* 2011 Jul;39(1):279-85.
- (38) Xie L *et al.* Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach. *Chem Pharm Bull (Tokyo).* 2011;59(8):984-90.

- (39) Wang SJ *et al.* Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF- κ B pathway. *Cancer Chemother Pharmacol.* 2011 Dec;68(6):1421-30
- (40) Wu J *et al.* Down-regulation of BMI-1 cooperates with Artemisinin on growth inhibition of nasopharyngeal carcinoma cells. *J Cell Biochem.* 2011 Mar 28.
- (41) Xu Q *et al.* Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. *J Zhejiang Univ Sci B.* 2011 Apr.;12(4):247-255.
- (42) Zhao Y *et al.* Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. *Int Immunopharmacol.* 2011 Dec;11(12):2039-46

2010 (37)

- (43) Chadwick J *et al.* Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. *Bioorg Med Chem.* 2010 Feb 23.
- (44) Chaturvedi D *et al.* Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. *Chem Soc Rev.* 2010 Feb;39(2):435-54.
- (45) Chen H *et al.* Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells. *Int J Hematol.* 2010 Oct 14.
- (46) Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derivatives. *Crit Rev Toxicol.* 2010 May;40(5):405-21.
- (47) Ferreira JF *et al.* Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer. *Molecules.* 2010 Apr 29;15(5):3135-70.
- (48) Ghantous A *et al.* What made sesquiterpene lactones reach cancer clinical trials? *Drug Discov Today.* 2010 Jun 8.
- (49) Gravett AM *et al.* In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. *Cancer Chemother Pharmacol.* 2010 May 19.
- (50) Hamacher-Brady A *et al.* Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalysed lysosomal reactive oxygen species production. *J Biol Chem.* 2010 Dec 13.
- (51) Handrick R *et al.* Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. *Mol Cancer Ther.* 2010 Jul 27.
- (52) He Q *et al.* Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. *Cancer Biol Ther.* 2010 May 18;9(10).

- (53) Hwang YP *et al.* Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKC α /Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. *Biochem Pharmacol.* 2010 Feb 10.
- (54) Langroudi L *et al.* A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. *Int Immunopharmacol.* 2010 Sep;10(9):1055-61.
- (55) Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. *Cancer Lett.* 2010 Aug 2.
- (56) Liu WM *et al.* The anti-malarial agent artesunate possesses anti-cancer properties that can be enhanced by combination strategies. *Int J Cancer.* 2010 Sep 30.
- (57) Lu JJ *et al.* Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. *Biochem Pharmacol.* 2010 Jul 1;80(1):22-30.
- (58) Lu JJ *et al.* The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. *Invest New Drugs.* 2010 Jul 7.
- (59) Lu YY *et al.* The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells. *FEBS Lett.* 2010 Aug 12.
- (60) Lu YY *et al.* Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques. *J Biomed Opt.* 2010 Jul-Aug;15(4):046028.
- (61) McGovern PE *et al.* Anticancer activity of botanical compounds in ancient fermented beverages (review). *Int J Oncol.* 2010 Jul;37(1):5-14.
- (62) Mercer AE *et al.* The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. *J Biol Chem.* 2010 Nov 8.
- (63) Morrissey C *et al.* Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. *Anticancer Drugs.* 2010 Apr;21(4):423-32.
- (64) O'Neill PM *et al.* The molecular mechanism of action of artemisinin--the debate continues. *Molecules.* 2010 Mar 12;15(3):1705-21.
- (65) Oh S *et al.* Acid-catalyzed synthesis of 10-substituted triazolyl artemisinins and their growth inhibitory activity against various cancer cells. *Bioorg Med Chem Lett.* 2010 Jun 8.
- (66) Ohgami Y *et al.* Effect of hyperbaric oxygen on the anticancer effect of artemisinin on molt-4 human leukemia cells. *Anticancer Res.* 2010 Nov;30(11):4467-70.

- (67) Rasheed SA *et al.* First evidence that the anti-malarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. *Int J Cancer*. 2010 Mar 15.
- (68) Schnepf N *et al.* Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells. *Antiviral Res*. 2011 Feb;89(2):186-8.
- (69) Sertel S *et al.* Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. *Molecules*. 2010 Apr 22;15(4):2886-910.
- (70) Sertel S *et al.* Factors determining sensitivity or resistance of tumor cell lines towards artesunate. *Chem Biol Interact*. 2010 Apr 15;185(1):42-52.
- (71) Soomro S *et al.* Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. *J Cell Mol Med*. 2010 Jul 12.
- (72) Steinbrück L *et al.* Effects of artesunate on cytokinesis and g2/m cell cycle progression of tumour cells and budding yeast. *Cancer Genomics Proteomics*. 2010 Nov-Dec;7(6):337-46.
- (73) Wang SJ *et al.* Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer. *Zhonghua Wai Ke Za Zhi*. 2010 Apr 1;48(7):530-4.
- (74) Wang SJ *et al.* Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. *Cancer Lett*. 2010 Jul 1;293(1):99-108.
- (75) Weifeng T *et al.* Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. *Phytomedicine*. 2010 Aug 23.
- (76) Wu XL *et al.* Effects of artemisinin on proliferation, apoptosis and caspase-3 expression of rat mesangial cell. *Zhong Yao Cai*. 2010 Mar;33(3):407-10.
- (77) Youns M *et al.* Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumours. *Curr Drug Discov Technol*. 2010 Mar 1;7(1):37-45.
- (78) Zeng QP, Zhang PZ. Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. *Nitric Oxide*. 2010 Dec 17.
- (79) Zhai DD *et al.* Inhibition of tumor cell proliferation and induction of apoptosis in human lung carcinoma 95-D cells by a new sesquiterpene from hairy root cultures of *Artemisia annua*. *Phytomedicine*. 2010 Mar 31.
- (80) Zhang S *et al.* Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. *Chem Biol Interact*. 2010 Mar 31.

- (81) Cai X *et al.* Artesunate induced morphological and mechanical changes of Jurkat cell studied by AFM. *Scanning*. 2009 Mar-Apr;31(2):83-9.
- (82) Chen H *et al.* Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. *J Cancer Res Clin Oncol*. 2009 Nov 26.
- (83) Chen H *et al.* Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. *Anticancer Drugs*. 2009 Feb;20(2):131-40.
- (84) Chen Y *et al.* Study of artemisinin nanocapsules as anticancer drug delivery systems. *Nanomedicine*. 2009 Jan 18.
- (85) Cho S *et al.* Synthesis of 10-substituted triazolyl artemisinins possessing anticancer activity via Huisgen 1,3-dipolar cycloaddition. *Bioorg Med Chem Lett*. 2009 Jan 15;19(2):382-5.
- (86) Chow LM, Chan TH. Novel classes of dimer antitumour drug candidates. *Curr Pharm Des*. 2009;15(6):659-74.
- (87) Du JH *et al.* Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. *Cancer Chemother Pharmacol*. 2009 Aug 19.
- (88) Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. *Expert Rev Mol Med*. 2009 Oct 30;11:e32.
- (89) Jones M *et al.* Antitumour and antimalarial activity of artemisinin-acridine hybrids. *Bioorg Med Chem Lett*. 2009 Apr 1;19(7):2033-7.
- (90) Konkimalla VB *et al.* The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate's activity in cancer cells. *Curr Cancer Drug Targets*. 2009 Feb;9(1):72-80.
- (91) Lai H *et al.* Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. *Anticancer Res*. 2009 Oct;29(10):3807-10.
- (92) Li S *et al.* Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. *Int J Hematol*. 2009 Aug 29.
- (93) Lu YY *et al.* Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. *J Biomed Sci*. 2009 Feb 2;16:16.
- (94) Michaelis M *et al.* Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. *Biochem Pharmacol*. 2009 Aug 19.
- (95) Noori S *et al.* Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. *Int Immunopharmacol*. 2009 Nov 6.

- (96) Ramacher M *et al.* Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. *Anticancer Drugs*. 2009 Sep 9.
- (97) Riganti C *et al.* Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1 α and P-glycoprotein overexpression. *Br J Pharmacol*. 2009 Apr;156(7):1054-66.
- (98) Ríos JL *et al.* Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer. *Curr Pharm Des*. 2009;15(11):1212-37.
- (99) Rosenthal AS *et al.* Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. *J Med Chem*. 2009 Feb 26;52(4):1198-203.
- (100) Sieber S *et al.* Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. *Int J Oncol*. 2009 Jul;35(1):149-58.
- (101) Slade D *et al.* Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers. *Bioorg Med Chem*. 2009 Dec 1;17(23):7949-57.
- (102) Stockwin LH *et al.* Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. *Int J Cancer*. 2009 Apr 7.
- (103) Wang L *et al.* Quantitative analysis of caspase-3 activation by fitting fluorescence emission spectra in living cells. *Micron*. 2009 Jul 23.
- (104) Wu ZP *et al.* Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. *Integr Cancer Ther*. 2009 Mar;8(1):88-92.
- (105) Yang X *et al.* Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells. *Bioorg Med Chem Lett*. 2009 May 27.
- (106) Youns M *et al.* Gene expression profiling identifies novel key players involved in the cytotoxic effect of artesunate on pancreatic cancer cells. *Biochem Pharmacol*. 2009 Aug 1;78(3):273-83.
- (107) Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. *PLoS One*. 2009 Oct 28;4(10):e7472.
- (108) Zhou HJ *et al.* Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. *Cancer Chemother Pharmacol*. 2009 Sep 16.

- (109) Konkimalla VB *et al.* Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. *Nitric Oxide*. 2008 Apr 22
- (110) Buommino E *et al.* Artemisinin reduces human melanoma cell migration by down-regulating alphaVbeta3 integrin and reducing metalloproteinase 2 production. *Invest New Drugs*. 2008 Oct 28.
- (111) Cai HH *et al.* Electrochemical activity of holotransferrin and its electrocatalysis-mediated process of artemisinin. *Bioorg Med Chem Lett*. 2008 Dec 6.
- (112) Chadwick J *et al.* Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against *P. falciparum* malaria parasites and HL-60 cancer cells. *Bioorg Med Chem*. 2008 Dec 24.
- (113) Chen T *et al.* Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. *J Cell Mol Med*. 2008 May 2
- (114) Fujita T *et al.* Human fortilin is a molecular target of dihydroartemisinin. *FEBS Lett*. 2008 Apr 2;582(7):1055-60. Epub 2008 Mar 4.
- (115) Galal AM *et al.* Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. *Bioorg Med Chem*. 2008 Nov 25
- (116) He RR, Zhou HJ. Progress in research on the anti-tumor effect of artesunate. *Chin J Integr Med*. 2008 Dec;14(4):312-6. Epub 2008 Dec 12.
- (117) Huang XF *et al.* Artesunate induces prostate cancer cell line PC-3 differentiation and cell cycle arrest [Article in Chinese]. *Zhong Xi Yi Jie He Xue Bao*. 2008 Jun;6(6):591-4.
- (118) Hosoya K *et al.* Biological activity of dihydroartemisinin in canine osteosarcoma cell lines. *Am J Vet Res* 2008;69:519–526.
- (119) Hou J *et al.* Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. *Clin Cancer Res*. 2008 Sep 1;14(17):5519-30.
- (120) Huang XJ *et al.* Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. *Pharmacology*. 2008 Apr 11;82(1):1-9
- (121) Kim SH *et al.* Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKCalpha/ERK pathway. *Eur J Pharmacol*. 2008 Apr 1
- (122) Krishna S *et al.* Artemisinins: their growing importance in medicine. *Trends Pharmacol Sci*. 2008 Aug 25.

- (123) Lai JP, Huang J. Suppressive effect of artesunate on k562 cell growth and its influence on VEGF expression. [Article in Chinese] *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2008 Aug;16(4):777-80.
- (124) Li LN *et al.* Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. *Eur J Pharmacol*. 2008 Apr 3.
- (125) Li PC *et al.* Artesunate derived from traditional Chinese medicine induces DNA damage and repair. *Cancer Res*. 2008 Jun 1;68(11):4347-4351.
- (126) Lu JJ *et al.* Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. *Cancer Biol Ther*. 2008 Apr 4;7(7).
- (127) Nakase I *et al.* Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. *Cancer Lett*. 2008 Nov 8.
- (128) Oh S, Kim BJ, Singh NP, Lai H, Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. *Cancer Lett*. 2008 Oct 4.
- (129) Potawale SE *et al.* Research and medicinal potential of *Artemisia annua*: a review. *Pharmacology Online*, 220-235 (2008).
- (130) Salminen A *et al.* Terpenoids: natural inhibitors of NF-kappaB signaling with anti-inflammatory and anticancer potential. *Cell Mol Life Sci*. 2008 Oct;65(19):2979-99.
- (131) Sundar SN *et al.* Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen induced proliferation in human breast cancer cells. *Carcinogenesis*. 2008 Sep 10.
- (132) Tan XJ *et al.* Effects of dihydroartemisinin on the adhesion, migration, and invasion of epithelial ovarian cancer cells [Chinese]. *Zhonghua Yi Xue Za Zhi*. 2008 Oct 14;88(37):2642-6.
- (133) Wang J *et al.* Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. *Pharmacology*. 2008 Jul 30.
- (134) Wang L *et al.* Influence of compatibility of artemisinin and mitomycin sera on proliferation of sarcoma A549 in vitro. *Zhongguo Yaoye* 17, 8-9, 2008.
- (135) Wang Z, Zhou HJ. Dihydroartemisinin down-regulates the expression of transferrin receptor in myeloid leukemia cells [Article in Chinese]. *Yao Xue Xue Bao*. 2008 Jun;43(6):576-83.

- (136) Willoughby Sr JA *et al.* Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 promoter and inhibiting CDK4 gene expression. *J Biol Chem.* 2008 Nov 17.
- (137) Wohlfarth C, Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C. *Acta Pharmacol Sin.* 2008 Dec 8.
- (138) Yao L *et al.* Analyzing anti-cancer action mechanisms of dihydroartemisinin using gene chip [Article in Chinese]. *Zhongguo Zhong Yao Za Zhi.* 2008 Jul;33(13):1583-6.
- (139) Yu Z *et al.* A new probe for targeting drug delivery system. *Med Hypotheses.* 2008 Sep 29.
- (140) Zhang ZY *et al.* Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. [Article in Chinese]. *Zhong Xi Yi Jie He Xue Bao.* 2008 Mar;6(2):134-8.
- (141) Zheng JS *et al.* Artesunate suppresses human endometrial carcinoma RL95-2 cell proliferation by inducing cell apoptosis [Article in Chinese]. *Nan Fang Yi Ke Da Xue Xue Bao.* 2008 Dec;28(12):2221-3.
- (142) Zhou HJ *et al.* Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. *Anti-Cancer Drugs.* 19(3):247-255, Mar 2008.

2007 (23)

- (143) Deng XR *et al.* Inhibitory effect of artemisinin on hepatoma H22 cells. *Shiyong Linchuang Yixue* 8, 1-3, 7, 2007.
- (144) Efferth T *et al.* From traditional Chinese medicine to rational cancer therapy. *Trends Mol Med.* 2007 Jul 16.
- (145) Efferth T. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. *PLoS ONE.* 2007 Aug 1;2:e693.
- (146) Efferth T. Willmar Schwabe Award 2006: Antiplasmodial and Antitumor Activity of Artemisinin - From Bench to Bedside. *Planta Med.* 2007 Mar 12;
- (147) Huang XJ *et al.* Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. *J Pharm Pharmacol.* 2007 Jun;59(6):849-56.
- (148) Jiao Y *et al.* Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. *Acta Pharmacol Sin.* 2007 Jul;28(7):1045-56.

- (149) Kelter G *et al.* Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. *PLoS ONE*. 2007 Aug 29;2(8):e798.
- (150) Lee S. Artemisinin, promising lead natural product for various drug developments. *Mini Rev Med Chem*. 2007 Apr;7(4):411-22.
- (151) Li LN *et al.* Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. *Int J Cancer*. 2007 Sep 15;121(6):1360-5.
- (152) Liu JL *et al.* Apoptosis of HL-60 cells induced by artesunate in vitro [Article in Chinese]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2007 Jun;15(3):506-9.
- (153) Ma ZQ *et al.* Dihydroartemisinin inhibits proliferation and induces apoptosis of rat glioma C6 cells [Article in Chinese]. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2007 May;36(3):267-72.
- (154) Mercer AE *et al.* Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. *J Biol Chem*. 2007 Jan 16.
- (155) Mu D *et al.* The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. *Cancer Chemother Pharmacol*. 2007 Jul 4.
- (156) Mu D *et al.* Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells. *Methods Find Exp Clin Pharmacol*. 2007 Jan-Feb;29(1):33-8.
- (157) Nakase H, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. *Int. J. Pharmaceutics*. 2007 in press.
- (158) Nam W *et al.* Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. *Head Neck*. 2007 Apr;29(4):335-40.
- (159) Sen R *et al.* Artemisinin triggers induction of cell-cycle arrest and apoptosis in *Leishmania donovani* promastigotes. *J Med Microbiol*. 2007 Sep;56(Pt 9):1213-8.
- (160) Utzinger J *et al.* Artemisinins for schistosomiasis and beyond. *Curr Opin Investig Drugs*. 2007 Feb;8(2):105-16.
- (161) Wang J *et al.* Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. *Pharmacology*. 2007 Jul 4;80(4):207-218.
- (162) Wang J *et al.* The inhibitory effect of artesunate on human esophageal carcinoma associated with modulation of CDC25A and TGF beta. *Zhongliu* 27, 272-276, 2007.

- (163) Yuan D *et al.* Effect of artesunate on prostate cancer cell line PC-3. *Zhongguo Yiyuan Yaoxue Zazhi* 27, 1049-1051, 2007.
- (164) Zheng ZY *et al.* Immune response of dendritic cells capturing antigens from apoptotic U937 cells induced by artesunate [Article in Chinese]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2007 Aug;15(4):833-8.
- (165) Zhou HJ *et al.* Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. *Vascul Pharmacol*. 2007 Aug-Sep;47(2-3):131-8.

2006 (17)

- (166) Alagbala AA *et al.* Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. *Med Chem*. 2006 Dec 28;49(26):7836-42.
- (167) Anfosso L *et al.* Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. *Pharmacogenomics J*. 2006 Jul-Aug;6(4):269-78. Epub 2006 Jan 24.
- (168) Cui C *et al.* Influence of artesunate and oxymatrine on immunosuppressive effect of mouse colon-rectal carcinoma cell line. *Xiandai Mianyixue* 26, 152-156 (2006).
- (169) Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. *Curr Drug Targets*. 2006 Apr;7(4):407-21.
- (170) Fan Y *et al.* Effects of artesunate on anoikis resistance in human breast cancer cell MCF-7. *Zhongguo Bingli Shengli Zazhi* 22, 748-751 (2006).
- (171) Golenser J *et al.* Current perspectives on the mechanism of action of artemisinins. *Int J Parasitol*. 2006 Dec;36(14):1427-41.
- (172) Han Z *et al.* Radiation Sensitizing Effect of Artemisinin, an Old Anti-Malaria Drug. *Int J Radiat Oncol Biol Phys*. Vol 66 (3): S553
- (173) Kim BJ, Sasaki T. Recent progress in the synthesis of artemisinin and its derivatives. *Org. Prep. Proc, Int*. 2006, 38(1), 1-80.
- (174) Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer in the rat. *Cancer Letters*. 2006 Jan 8; 231(1):43-8.
- (175) Lee J *et al.* Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. *Cancer Chemother Pharmacol*. 2006 Jan;57(2):213-20.

- (176) Paik IH *et al.* Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. *J Med Chem.* 2006 May 4;49(9):2731-4.
- (177) Posner GH *et al.* Anticancer activity of artemisinin-derived trioxanes. *Expert Opin Ther Pat.* Vol 16, No 12, Dec 2006.
- (178) Sagar SM *et al.* Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. *Curr Oncol.* 2006 Feb;13(1):14-26.
- (179) Sagar SM *et al.* Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. *Curr Oncol.* 2006 Jun;13(3):99-107.
- (180) Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. *Integr Cancer Ther.* 2006 Dec;5(4):391-4.
- (181) Toler SM *et al.* Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme. *Neurosurg Focus.* 2006 Dec 15;21(6):E10.
- (182) Wu XH *et al.* Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. *Anticancer Drugs.* 2006 Aug;17(7):839-48.
- (183) Yance DR Jr, Sagar SM. Targeting angiogenesis with integrative cancer therapies. *Integr Cancer Ther.* 2006 Mar;5(1):9-29.

2005 (12)

- (184) Berger TG *et al.* Artesunate in the treatment of metastatic uveal melanoma--first experiences. *Oncol Rep.* 2005 Dec; 14(6):1599-603.
- (185) Disbrow GL *et al.* Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. *Cancer Research.* 2005 Dec 1; 65(23):10854-61.
- (186) Efferth T, Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. *In Vivo.* 2005 Jan-Feb;19(1):225-32.
- (187) Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. *Drug Resist Update.* 2005 Feb-Apr; 8(1-2):85-97.
- (188) Kim SJ *et al.* Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. *J Cancer Res Clin Oncol.* 2006 Feb; 132(2):129-35. Epub 2005 Nov 5.

- (189) Lai H, Sasaki T, Singh NP, Massey A. Effects of artemisinin-tagged holotransferrin on cancer cells. *Life Sciences* 76:1267-1279, 2005.
- (190) Lai H, Sasaki T, Singh NP. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. *Expert Opin Ther Targets*. 2005 Oct; 9(5):995-1007.
- (191) Li J, Zhou HJ. Dihydroartemisinin inhibits the expression of vascular endothelial growth factor in K562 cells [Article in Chinese]. *Yao Xue Xue Bao*. 2005 Nov;40(11):1041-5.
- (192) Li W *et al*. Yeast model uncovers dual roles of mitochondria in action of artemisinin. *PLoS Genet*. 2005 Sep;1(3):e36.
- (193) Liu Y *et al*. Synthesis and cytotoxicity studies of artemisinin derivatives containing lipophilic alkyl carbon chains. *Org Lett*. 2005 Apr 14;7(8):1561-4.
- (194) Singh NP, Lai H. Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. *Anticancer Research*. 2005 Nov-Dec; 25(6B):4325-31.
- (195) Zhang S *et al*. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. *Curr Med Chem Anticancer Agents*. 2005 May;5(3):239-49.

2004 (15)

- (196) Chen HH *et al*. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. *Pharmacology*. 2004 May; 71(1):1-9.
- (197) Chen HH *et al*. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. *Cancer Lett* 211(2):163-73, 2004.
- (198) Dell'Eva R *et al*. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. *Biochem Pharmacol*. 2004 Dec 15; 68(12):2359-66.
- (199) Efferth T *et al*. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. *Free Radic Biol Med*. 2004 Oct 1; 37(7):998-1009.
- (200) Efferth T *et al*. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. *Biochem Pharmacol*. 2004 May 1;67(9):1689-700.

- (201) Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinin and anthracyclines. *Biochem Pharmacol.* 2004 Jul 1; 68(1):3-10.
- (202) Jeyadevan JP *et al.* Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10beta-(2-hydroxyethyl) deoxyartemisinin. *J Med Chem.* 2004 Feb 26; 47(5):1290-8.
- (203) Jung M *et al.* Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. *Curr Med Chem.* 2004 May;11(10):1265-84.
- (204) Li Y *et al.* Induction of apoptosis of cultured hepatocarcinoma cell by essential oil of *Artemisia annua* L. [Article in Chinese]. *Sichuan Da Xue Xue Bao Yi Xue Ban.* 2004 May;35(3):337-9.
- (205) Oh S *et al.* Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. *Bioorg Med Chem.* 2004 Jul 15;12(14):3783-90.
- (206) Posner GH *et al.* Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. *J Med Chem.* 2004 Feb 26;47(5):1299-301.
- (207) Rinner B *et al.* Activity of novel plant extracts against medullary thyroid carcinoma cells. *Anticancer Res.* 2004 Mar-Apr;24(2A):495-500.
- (208) Singh NP, Lai H. Artemisinin induces apoptosis in human cancer cells. *Anticancer Research* 24:2277-2280, 2004.
- (209) Wu GD *et al.* Apoptosis of human umbilical vein endothelial cells induced by artesunate. *Vascul Pharmacol.* 2004 Jul;41(6):205-12.
- (210) Yamachika E *et al.* Artemisinin: an alternative treatment for oral squamous cell carcinoma. *Anticancer Res.* 2004 Jul-Aug; 24(4):2153-60.

2003 (9)

- (211) Chen HH *et al.* Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. *Pharmacol Res.* 2003 Sep; 48(3):231-6.
- (212) Efferth T *et al.* Molecular modes of action of artesunate in tumor cell lines. *Mol Pharmacol.* 2003 Aug;64(2):382-94.
- (213) Efferth T *et al.* Role of antioxidant genes for the activity of artesunate against tumor cells. *Int J Oncol.* 2003 Oct;23(4):1231-5.

- (214) Kim SH *et al.* Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin. *Eur J Pharmacol.* 2003 Dec 15; 482(1-3):67-76.
- (215) McCarty MF. Turning an 'Achilles' Heel' into an asset--activation of HIF-1alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage. *Med Hypotheses.* 2003 Oct; 61(4):509-11.
- (216) Oh S *et al.* Growth inhibition activity of thioacetal artemisinin derivatives against human umbilical vein endothelial cells. *Bioorg Med Chem Lett.* 2003 Nov 3;13(21):3665-8.
- (217) Payne AG. Exploiting intracellular iron and iron-rich compounds to effect tumor cell lysis. *Med Hypotheses.* 2003 Aug;61(2):206-9.
- (218) Posner GH *et al.* Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. *J Med Chem.* 2003 Mar 13;46(6):1060-5.
- (219) Wartenberg M *et al.* The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. *Lab Invest.* 2003 Nov;83(11):1647-55.

2002 (10)

- (220) Efferth T *et al.* mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. *Biochem Pharmacol.* 2002 Aug 15; 64(4):617-23.
- (221) Efferth T *et al.* Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. *J Mol Med.* 2002 Apr;80(4):233-42. Epub 2001 Dec 8.
- (222) Efferth T *et al.* Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. *Blood Cells Mol Dis.* 2002 Mar-Apr;28(2):160-8.
- (223) Galal AM *et al.* Deoxyartemisinin derivatives from photooxygenation of anhydrodeoxydihydroartemisinin and their cytotoxic evaluation. *J Nat Prod.* 2002 Feb;65(2):184-8.
- (224) Mukanganyama S *et al.* Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. *Int J Cancer* 97:700-705, 2002.

- (225) Posner GH *et al.* New chemical and biological aspects of artemisinin-derived trioxane dimers. *Bioorg Med Chem.* 2002 Jan;10(1):227-32.
- (226) Reungpatthanaphong P and Mankhetkorn S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. *Biol Pharm Bull.* 2002 Dec; 25(12):1555-61.
- (227) Sadava D *et al.* Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. *Cancer Letters* 2002 May 28; 179(2):151-6.
- (228) Singh NP, Verma KB. Case report of a laryngeal squamous cell carcinoma treated with artesunate. *Arch Oncol* 10:279-280, 2002.
- (229) Wang Q *et al.* The anticancer effect of artesunate and its mechanism [Article in Chinese]. *Yao Xue Xue Bao.* 2002 Jun;37(6):477-8.

2001 (6)

- (230) Efferth T *et al.* The anti-malarial artesunate is also active against cancer. *Int J Oncol.* 2001 Apr; 18(4):767-73.
- (231) Li Y *et al.* Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. *Bioorg Med Chem Lett* 11:5-8, 2001.
- (232) Mukanganyama S *et al.* Proposed reductive metabolism of artemisinin by glutathione transferases in vitro. *Free Radic Res.* 2001 Oct;35(4):427-34.
- (233) Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin on human breast cancer cells. *Life Sciences* 70:49-56, 2001.
- (234) Wang Q *et al.* Experimental studies of antitumor effect of artesunate on liver cancer [Article in Chinese]. *Zhongguo Zhong Yao Za Zhi.* 2001 Oct;26(10):707-8, 720.
- (235) Wu JM *et al.* Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. *Eur J Med Chem.* 2001 May;36(5):469-79.

2000 (1)

- (236) Lee CH *et al.* NMR studies on novel antitumor drug candidates, deoxoartemisinin and carboxypropyldeoxoartemisinin. *Biochem Biophys Res Comm* 274:359-369, 2000.

Before 2000 (14)

- (237) Beekman AC *et al.* Cytotoxicity of artemisinin, a dimer of dihydroartemisinin, artemisitene and aupatoriopicrin as evaluated by the MTT and clonogenic assay. *Phytother Res.* 1998 Dec;10(2):140-144.
- (238) Beekman AC *et al.* Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells. *J Pharm Pharmacol* 49:1254-1258, 1997.
- (239) Beekman AC *et al.* Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. *Planta Med* 64:615-619, 1998.
- (240) Beekman AC *et al.* Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. *J Nat Prod* 60:325-330, 1997.
- (241) Deng DA *et al.* Derivatives of arteannuin B with antileukemia activity [Article in Chinese]. *Yao Xue Xue Bao.* 1992;27(4):317-20.
- (242) Efferth T *et al.* Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. *Arzneimittelforschung.* 1996 Feb;46(2):196-200.
- (243) Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. *Cancer Letters* 91:41-46, 1995.
- (244) Moore JC *et al.* Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. *Cancer Letters* 98:83-87, 1995.
- (245) Posner GH *et al.* Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. *J Med Chem.* 1999 Oct 21;42(21):4275-80.
- (246) Shen M *et al.* Immunosuppressive action of Qinghaosu. *Sci Sin B.* 1984 Apr;27(4):398-406.
- (247) Sun WC *et al.* Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro [Article in Chinese]. *Zhongguo Yao Li Xue Bao* 13:541-543, 1992.
- (248) Woerdenbag HJ *et al.* Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. *J Nat Prod* 56:849-856, 1993.
- (249) Woerdenbag HJ *et al.* Cytotoxicity of flavonoids and sesquiterpene lactones from Arnica species against the GLC4 and the COLO 320 cell lines. *Planta Med* 60:434-437, 1994.
- (250) Zheng GQ. Cytotoxic terpenoids and flavonoids from *Artemisia annua*. *Planta Med* 60:54-57, 1994.